PH25426A - Antischizoprenic-s-n(1-azabicyclo£2.2.2|oct-3-yl)benzamides, thiobenzamides - Google Patents

Antischizoprenic-s-n(1-azabicyclo£2.2.2|oct-3-yl)benzamides, thiobenzamides

Info

Publication number
PH25426A
PH25426A PH39032A PH39032A PH25426A PH 25426 A PH25426 A PH 25426A PH 39032 A PH39032 A PH 39032A PH 39032 A PH39032 A PH 39032A PH 25426 A PH25426 A PH 25426A
Authority
PH
Philippines
Prior art keywords
chem
general formula
azabicyclo
oct
alkyl
Prior art date
Application number
PH39032A
Other languages
English (en)
Inventor
Alain Renaud
Michel Langlois
Robert John Naylor
Brenda Naylor
Original Assignee
Delalande Sa
Robins Co Inc A H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delalande Sa, Robins Co Inc A H filed Critical Delalande Sa
Publication of PH25426A publication Critical patent/PH25426A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH39032A 1988-08-04 1989-08-01 Antischizoprenic-s-n(1-azabicyclo£2.2.2|oct-3-yl)benzamides, thiobenzamides PH25426A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88402042A EP0353372B1 (en) 1988-08-04 1988-08-04 Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides

Publications (1)

Publication Number Publication Date
PH25426A true PH25426A (en) 1991-07-01

Family

ID=8200415

Family Applications (1)

Application Number Title Priority Date Filing Date
PH39032A PH25426A (en) 1988-08-04 1989-08-01 Antischizoprenic-s-n(1-azabicyclo£2.2.2|oct-3-yl)benzamides, thiobenzamides

Country Status (11)

Country Link
US (1) US5025022A (ja)
EP (1) EP0353372B1 (ja)
JP (1) JPH02104529A (ja)
KR (1) KR900002777A (ja)
AT (1) ATE85217T1 (ja)
AU (1) AU615323B2 (ja)
DE (1) DE3878235T2 (ja)
DK (1) DK382089A (ja)
IL (1) IL91217A0 (ja)
PH (1) PH25426A (ja)
ZA (1) ZA895842B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353371A1 (en) * 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282873A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
JP2005504059A (ja) * 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
EP1442041A1 (en) * 2001-11-08 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
CA2476417A1 (en) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
EP1478646A1 (en) * 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
WO2004013137A1 (en) 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US8435762B2 (en) 2008-10-09 2013-05-07 Howard Hughes Medical Institute Chimeric ligand-gated ion channels and methods of use thereof
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
CN115427038A (zh) 2020-02-03 2022-12-02 建新公司 治疗与溶酶体贮积病相关的神经系统症状的方法
BR112023000798A2 (pt) 2020-07-24 2023-02-07 Genzyme Corp Composições farmacêuticas compreendendo venglustat

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
FR2529548A1 (fr) * 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
GB8515845D0 (en) * 1985-06-22 1985-07-24 Beecham Group Plc Treatment
EP0235878A3 (en) * 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds
PH23937A (en) * 1986-12-16 1990-01-23 Robins Co Inc A H Anxiolytic-n-(1-azabicyclo(2.2.2.)oct-3-yl)benzamides and thiobenzamides
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
US4857517A (en) * 1988-02-04 1989-08-15 Rorer Pharmaceutical Corporation Quinuclidyl benzoxepins as 5-HT3 antagonists
EP0353371A1 (en) * 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides

Also Published As

Publication number Publication date
DK382089A (da) 1990-02-05
DK382089D0 (da) 1989-08-03
JPH02104529A (ja) 1990-04-17
ZA895842B (en) 1991-03-27
EP0353372B1 (en) 1993-02-03
KR900002777A (ko) 1990-03-23
EP0353372A1 (en) 1990-02-07
IL91217A0 (en) 1990-07-12
DE3878235D1 (de) 1993-03-18
DE3878235T2 (de) 1993-06-03
AU3917889A (en) 1990-02-08
US5025022A (en) 1991-06-18
ATE85217T1 (de) 1993-02-15
AU615323B2 (en) 1991-09-26

Similar Documents

Publication Publication Date Title
PH25426A (en) Antischizoprenic-s-n(1-azabicyclo£2.2.2|oct-3-yl)benzamides, thiobenzamides
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
AU591640B2 (en) Quinolonecarboxylic acid derivatives
AU627832B2 (en) Imidazo(1,2-6)pyridazines, their production and use
EP0612751A3 (en) Compounds for the preparation of cephem derivatives.
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
NO940831D0 (no) Diiodforbindelser for anvendelse ved fremstilling av morfolinylderivater av doxorubicin, og deres fremstilling
PH25429A (en) 2-alkoxy-n-(1-azabicyclo£2.2.2|oct-3-yl)benzamides, thiobenzamides
EP0273744A3 (en) Centrally-acting muscle relaxants
ES8101646A1 (es) Un procedimiento para producir un compuesto opticamente ac- tivo
DE68913099D1 (de) Amino-substituierte verbrückte azabicyclische Chinoloncarbonsäure und Ester.
AU586089B2 (en) Phosphodiesterace type 111 inhibitors having a thiadiazinone ring as part of a tricyclic structure